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Abstract
Background: Insulin glargine 300U/mL (Gla-300) has a more constant and prolonged action profile than insulin
glargine 100U/mL and in clinical studies is associated with similar glycemic control but less hypoglycemia.
Whether its effects are altered by variability of injection time was examined in two 3-month substudies.
Materials and Methods: Eligible participants completing 6 months of optimized treatment with Gla-300 in
EDITION 1 (n = 109) and EDITION 2 (n = 89), having a mean hemoglobin A1c (HbA1c) level of 7.3 % (SD
1.0 %), were randomized (1:1) to groups advised to increase variability of between-injection intervals to 24 – up
to 3 h or to maintain fixed 24-h intervals for 3 months. Changes of HbA1c level and other efficacy and safety
measures were assessed.
Results: In the fixed-dosing group, 64% of participants reported all intervals within the 23–25-h range, com-
pared with 15% of those advised flexible dosing. In the fixed- and flexible-dosing groups, 12% and 41%,
respectively, of between-injection intervals were outside the 23–25-h range, and 2% and 16%, respectively,
were outside the 21–27-h range. Least squares mean between-group difference in HbA1c change from baseline
was 0.05 % (95% confidence interval [CI], -0.13 to 0.23); for fasting plasma glucose, 2.7mg/dL (95% CI, -9.0
to 14.4); and for daily basal insulin dose, 0.00U/kg (95% CI, -0.02 to 0.03). Frequencies of hypoglycemia and
adverse events did not differ between groups.
Conclusions: The efficacy and safety of Gla-300 demonstrated in EDITION 1 and EDITION 2 are maintained
in substudies when the insulin was injected up to 3 h before or after the usual time of administration.
Introduction
New insulin glargine 300U/mL (Gla-300) has beenshown to display more constant and prolonged pharmaco-
kinetic and pharmacodynamic profiles compared with insulin
glargine 100U/mL (Gla-100).1 Comparisons of the clinical
outcomes with Gla-300 versus Gla-100 in the EDITION 1 and
EDITION 2 studies (registered with clinical trial registration
numbers NCT01499082 and NCT01499095, respectively,
at ClinicalTrials.gov) in people with type 2 diabetes
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mellitus (T2DM) have demonstrated that Gla-300 provides
equivalent glycemic control to Gla-100 but with a lower
risk of hypoglycemia.2,3 However, results of structured
clinical studiesmay not always predict the results of treatments
when they are applied in usual medical practice, in part
because adherence to the timing of insulin injections may be
more rigorous in the research setting. The pharmacokinetic
and pharmacodynamic profiles of Gla-300, which extend
beyond 24 h,1 may additionally allow greater flexibility in
basal insulin injection time, permitting people to adapt in-
jection times to their daily lifestyle needs.
To investigate the efficacy and safety ofGla-300when there
is greater variability in the timingof injections, twopredefined,
3-month substudies were embedded within EDITION 1 and
EDITION 2. Here we describe analyses of data from these two
substudies, both pooled and considered separately.
Materials and Methods
Study design and participants
The EDITION1 andEDITION2 studies comparedGla-300
and Gla-100 in participants with T2DM using basal and
mealtime insulin (EDITION 1) or basal insulin and oral anti-
hyperglycemic drugs (EDITION 2).2,3 Following the main
6-month treatment period, 3-month substudieswere conducted
to examine the efficacy and safety of Gla-300 using flexible
dosing (24– up to 3 h) or fixed dosing (24 h) intervals (Fig. 1).
To enter the substudies the main study participants from the
Gla-300 group had to agree to take part in the substudy, in-
cluding the use of the flexible-dosing regimen, and tobe judged
by the investigator to be able to adhere to such a schedule.
Interventions
Immediately after the main 6-month treatment period of
EDITION 1 and EDITION 2, eligible participants previously
using Gla-300 were randomized (1:1) using a remote tele-
phone (interactive voice response system) or online system
(interactive Web response system) to continue with fixed
dosing or to start using a flexible-dosing regimen. Gla-300
was administered each evening using a modified SoloSTAR
(Sanofi, Paris, France) pen injector, with its dose usually ad-
justed weekly (and nomore often than every 3 days) seeking a
fasting self-measured plasma glucose of 80–100mg/dL (4.4–
5.6mmol/L) prior to breakfast, as in the main studies.2,3
Participants documented their daily basal insulin dosage and
time of administration. The reference injection times for all
individuals were established at the start of the main studies.
Participants in the flexible-dosing groups were instructed to
inject insulin doses within 3 h earlier or later than their in-
jection reference time (24– up to 3 h) and at the maximum
interval (i.e., 3 h earlier or later than the reference injection
time in the evening) on at least 2 days in each week. Partici-
pants in the fixed-dosing groups were instructed to continue
with the injection of basal insulin doses at their reference
injection time each evening, with 24 h between injections.
In the EDITION 1 substudy, mealtime insulin doses were
adjusted at the discretion of the investigator. In theEDITION2
substudy, if hemoglobinA1c (HbA1c) or fasting self-measured
plasma glucose measurements were above target values and
there was no reasonable explanation for inadequate glucose
control, or if appropriate action failed to decrease the levels to
below threshold values, rescue therapy could be considered by
the investigator, based on a thorough evaluation of the par-
ticipant’s glycemic control. The choice of rescue medication
was based on the investigator’s decision and local approved
guidelines. Assessment visits occurred at the baseline of each
substudy (Month 6 of the main EDITION studies) and at the
end of each 3-month substudy (Month 9 of themain EDITION
studies). Telephone interviews were conducted at Week 1,
Week 3, and Month 1.5 during each substudy.
Main EDITION study:
6-month treatment period
0 months 6 months 12 months9 months
Flexible dosing
Gla-300 once daily
every 24 ± up to 3 h 
Main EDITION study:
6-month extension period
Substudy:
3-month
Fixed dosing
Gla-300 once daily
every 24 h
Gla-100 once daily
every 24 h
Gla-300 once daily
every 24 h
FIG. 1. EDITION 1 and EDITION 2 study design. Gla-100, insulin glargine 100U/mL; Gla-300, insulin glargine 300U/mL.
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Outcomes
The time intervals between two consecutive injections in
the last 7 days before the assessments at Month 1.5 and
Month 3 (Month 7.5 and Month 9, respectively, of the main
EDITION studies) were analyzed. Thus, for each participant
two 7-day sequences of injections were available for analysis.
For purposes of analysis, dosing intervals were assigned to
the following categories: 24– up to 1 h (within a 23–25-h
interval), 24 – 1–3 h (within a 21–23-h or within a 25–27-h
interval), and 24–more than 3 h (beyond a 21–27-h interval).
The percentage of all between-injection intervals within or
outside each of these ranges was calculated. In addition, the
percentage of participants with all injection intervals in the
23–25-h range was determined.
The primary efficacy end point was the change in HbA1c
from substudy baseline to the end of the 3-month substudy.
Secondary end points included the change in laboratory-
measured (clinic-collected) fasting plasma glucose (FPG)
and daily basal insulin doses. Hypoglycemia occurring be-
tween the substudy baseline and the end of the substudy was
analyzed by categories defined by the American Diabetes
Association4 and was classified as occurring during the night
(‘‘nocturnal’’; 00:00–05:59 h) and at any time (24 h). Both
percentages of participants with one or more hypoglycemic
event and annualized rates (events per participant-year) were
calculated. Adverse events (AEs) were recorded.
Data analysis and statistics
Outcomes were assessed separately for each substudy, as
well as a pooled analysis of both. The individual substudy
data were analyzed using analysis of covariance with treat-
ment regimen and country as fixed effects and using the
corresponding baseline value (at 6 months of the main study)
as a covariate. A fixed-effect analysis based on the pooled
data from EDITION 1 and EDITION 2 was performed for the
modified intent-to-treat population (all participants who were
randomized in the substudies and who, in the substudies,
received at least one dose of Gla-300 and had an initial as-
sessment and one or more subsequent assessment). For the
change in HbA1c, FPG, and daily basal insulin dose from the
substudy baseline to the end of the 3-month substudy, anal-
ysis of covariance was performed with fixed categorical ef-
fects of treatment regimen and substudy, as well as the
continuous fixed covariates of corresponding baseline value.
Safety end points were analyzed descriptively using the
safety population, defined as all participants randomized
within the substudies and exposed to at least one dose of Gla-
300, regardless of dosage or duration.
Results
Study population
In total, 109 participants from EDITION 1 and 89 from
EDITION 2 were enrolled in the substudies. These 198 par-
ticipants were randomized to either the flexible-dosing
(n = 101) or fixed-dosing (n = 97) regimens. The safety pop-
ulation comprised 100 and 96 participants for the respective
regimens, and the modified intent-to-treat population in-
cluded 99 and 95 participants, respectively. Baseline (Month
6 in the main studies) age, gender distribution, body mass
index, and HbA1c for the randomized population were similar
between the flexible- and fixed-dosing groups within each
substudy and between the pooled flexible- and fixed-dosing
groups (Supplementary Table S1; Supplementary Data are
available online at www.liebertonline.com/dia).
Variability in dosing intervals
Data were available for 1,003 dosing intervals for 96 par-
ticipants in the fixed-dosing group and 1,092 dosing intervals
for 100 individuals in the flexible-dosing group. In the pooled
analysis, 64% of participants in the fixed-dosing group main-
tained all observed intervals in the 23–25-h range, compared
with just 15% of those in the flexible-dosing group. Of all
intervals observed in the fixed-dosing group, 88% were in the
23–25-h range (and thus 12% were outside that range),
whereas in comparison 59% of intervals in the flexible-dosing
group were in the 23–25-h range (41% outside the range).
Between-injection intervals outside the 21–27-h range were
uncommon for the fixed-dosing group (2%), but 16% of in-
tervals in the flexible-dosing group were outside this wider
range (Fig. 2). Within the individual substudies (Supplemen-
tary Fig. S1), the pattern of injection intervals was similar to
that observed in the pooled data.
Glycemic responses and insulin dosage
In the pooled analysis, HbA1c for both the flexible- and
fixed-dosing groups after 3 months was similar to that ob-
served at the substudy baseline (Table 1). The least squares
(LS) mean difference between regimens in the mean change
in HbA1c was 0.05 % (95% confidence interval [CI], -0.13 to
0.23) (0.5 [-1.4 to 2.5] mmol/mol). Laboratory-measured
(clinic-collected) FPG levels were also similar at substudy
baseline and after 3 months for both treatment regimens
(Table 1). The LS mean difference between the flexible- and
fixed-dosing regimens in mean FPG change was 2.7 (95%CI,
-9.0 to 14.4) mg/dL (0.15 [–0.50 to 0.80] mmol/L). The
change in mean daily basal insulin dose was identical, with
the LS mean difference being 0.00 (95% CI, -0.02 to 0.03)
U/kg between the treatment regimens (Table 1). The indi-
vidual data for the EDITION 1 and EDITION two substudies
are shown in Supplementary Table S2.
FIG. 2. Percentage of injections by the time interval be-
tween two consecutive insulin glargine 300U/mL injections
in EDITION1 andEDITION2 substudies (safety population).
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Hypoglycemia
The percentage of participants experiencing one or more
nocturnal confirmed (£70mg/dL [£3.9mmol/L]) or severe
hypoglycemic events was similar in the pooled data analysis,
at 21% and 23% in the flexible-dosing and fixed-dosing
groups, respectively (Fig. 3A and Supplementary Table S3).
This was also true for the events at any time (24 h) and for
nocturnal and any-time events analyzed using other defini-
tions of hypoglycemia (Fig. 3A and B and Supplementary
Table S3). One severe hypoglycemic event was reported in
the fixed-dosing group and none in the flexible-dosing group
(Supplementary Table S3).
Likewise, the annualized rates of hypoglycemia compared
using any definition, at any time (24 h) and during the night,
were similar with the flexible-dosing and fixed-dosing regi-
mens (Fig. 3C and D and Supplementary Table S3). The
occurrence of hypoglycemia is shown separately for EDI-
TION 1 and EDITION 2 in Supplementary Tables S4 and S5,
respectively.
AEs
The number of participants experiencing any treatment-
emergent AEs in the pooled data analysis was similar in both
the flexible-dosing and fixed-dosing groups (24 [24%] and 26
[27%], respectively). No signal for differences in any cate-
gory of event was detected. A comparably low number of
participants experienced serious AEs in the flexible- and
fixed-dosing groups (6 [6%] and 5 [5%], respectively). The
serious AEs were not considered related to the study medi-
cation, and no deaths were reported. No differences between
regimens within each substudy were detected.
Discussion
In clinical research studies comparing insulin regimens, the
timing of insulin injections is usuallymandated by protocol to
allow comparisons between the properties of the insulins
tested. However, both people with diabetes and physicians
agree that a daily fixed injection time is restrictive, and in real
life individuals often deviate from a fixed injection time in
order to adapt to daily changes of schedule.5,6 In one survey,
only 19%of physicians reported that their patients were ‘‘very
successful’’ at taking their insulin injection at a fixed time
every day.5 In a survey of people with diabetes,7 24% of
respondents reported they had mistimed their basal insulin
injection (–2 h from the prescribed injection time) on one or
more occasions in the previous 30 days, with a mean number
of 4.2 mistimed doses in the previous 30 days. Some indi-
viduals (6.5%) hadmistimed their injections onmore than five
occasions in the previous 30 days. In addition, 47% of people
in this survey reported that a fixed-dosing schedule negatively
affected many daily activities. Hence the results of clinical
studies may not always be reflected in clinical practice, when
people are less consistent in using insulin. New basal insulin
analogs with longer and more stable profiles of action might
be less affected by greater variation of injection time. Thus,
finding no loss of efficacy or safety when intervals between
injections of these agents are varied in research studies might
allay concerns that such studies are not relevant to clinical
practice.
These substudies of EDITION 1 and EDITION 2 were
designed to address this issue, in the setting of glycemic
control that had previously been optimized. The advice given
to participants in the flexible-dosing arm of the study clearly
increased the variability of injection timing compared with
that observed in the fixed-dosing interval arm, both with re-
gard to the number of participants with at least one interval
outside the 23–25-h range (85% vs. 36%) and in the per-
centage of all observed intervals outside the range (41% vs.
12%). Similarly, more extreme deviations of injection in-
tervals, greater than –3 h and thus outside a 21–27-h range,
were more frequent in the flexible-dosing group compared
Table 1. Clinical Measures for the Flexible-Dosing
and Fixed-Dosing Insulin Glargine 300U/mL
Regimens (Pooled Data, EDITION 1 and EDITION 2
Substudies, Modified Intent-to-Treat Population)
Flexible
dosing
(n = 99)
Fixed
dosing
(n= 95)
Daily basal insulin dose (U/kg)
Baseline of substudy
[mean (SD)]a
1.00 (0.36) 0.93 (0.33)
End of substudy
(Month 3) [mean (SD)]b
1.04 (0.39) 0.96 (0.37)
Baseline of substudy
to end of substudy
(Month 3) [LS
mean change (SE)]
0.03 (0.01) 0.03 (0.01)
LS difference [mean
(95% CI)]
0.00 (-0.02 to 0.03)
HbA1c
Baseline of substudy [mean (SD)]a
% 7.30 (0.93) 7.30 (0.96)
mmol/mol 56.3 (10.2) 56.3 (10.5)
End of substudy (Month 3) [mean (SD)]b
% 7.34 (0.92) 7.29 (1.03)
mmol/mol 56.7 (10.1) 56.2 (11.3)
Baseline of substudy to end of
substudy (Month 3) [LS mean change (SE)]
% 0.05 (0.06) 0.00 (0.07)
mmol/mol 0.5 (0.7) 0.0 (0.7)
LS difference [mean (95% CI)]
% 0.05 (-0.13 to 0.23)
mmol/mol 0.5 (-1.4 to 2.5)
FPG
Baseline of substudy [mean (SD)]a
mg/dL 130.2 (35.6) 124.2 (47.2)
mmol/L 7.2 (2.0) 6.9 (2.6)
End of substudy (Month 3) [mean (SD)]b
mg/dL 135.4 (42.1) 129.5 (48.6)
mmol/L 7.5 (2.3) 7.2 (2.7)
Baseline of substudy to end of substudy
(Month 3) [LS mean change (SE)]
mg/dL 6.6 (4.1) 3.9 (4.3)
mmol/L 0.37 (0.23) 0.22 (0.24)
LS difference [mean (95% CI)]
mg/dL 2.7 (-9.0 to 14.4)
mmol/L 0.15 (-0.50 to 0.80)
aMonth 6 of the main EDITION study.
bMonth 9 of the main EDITION study.
CI, confidence interval; FPG, fasting plasma glucose (central
laboratory-measured); HbA1c, hemoglobin A1c; LS, least squares;
mITT, modified intent-to-treat.
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with the fixed-dosing group (16% vs. 2%). The degree of
variability observed in the flexible-dosing group in this study
appears similar to that commonly seen in daily life, as re-
ported in the study described above,7 where the timing of
injections may be influenced by variations in timing of the
evening meal or bedtime, as required by work or family ac-
tivities, or by travel.
Therefore the present findings with Gla-300 provide re-
assurance that, given this much variability of injection tim-
ing, Gla-300 may be expected to have similar efficacy and
tolerability in routine clinical use as in EDITION 1 and
EDITION 2. Specifically, no differences between the treat-
ment regimens in glycemic control assessed by HbA1c or by
clinic-collected and laboratory-measured FPG were found,
and insulin doses were the same with each regimen. There
was no evidence that the occurrence of nonsevere hypogly-
cemia, defined as confirmed by glucose measurement of
£70mg/dL or <54mg/dL, was affected by greater flexibility
of timing. Severe hypoglycemic events were uncommon with
both regimens. Moreover, when data from each of the two
substudies embedded within EDITION 1 and EDITION 2
were considered separately, no clear differences were ap-
parent. Thus, increased flexibility of timing of Gla-300 in-
jection led to no difficulties in the setting of either mealtime
and basal insulin therapy or basal insulin without mealtime
insulin.
Of interest in relation to these findings with Gla-300 is a
previous report of use of insulin degludec, a basal insulin with
an even longer action profile than Gla-300, for T2DM.8 Be-
cause insulin degludec has a duration of action approaching
2 days (with a half-life of approximately 25 h),9 its efficacy
and safety were tested when it was administered with very
widely variable (8–40-h) dosing intervals and compared with
once-daily degludec and once-daily Gla-100 that were al-
ways to be injected at the same time of day. In addition to
testing dosing intervals that are well beyond those usually
recommended in clinical practice, the insulin degludec study
differed from the present study by including insulin-naive
participants, having a longer follow-up (26 weeks vs. 12
weeks), and enrollingmore participants in the variable dosing
arm (229 vs. 99). Under these conditions, variable dosing
intervals with insulin degludec resulted in equivalent levels
of glycemic control and similar rates of hypoglycemia to
fixed dosing intervals with either Gla-100 or insulin deglu-
dec, providing reassurance that substantially altering injec-
tion timing altered neither the risks nor the efficacy of insulin
degludec.
The strengths of our substudies include the success of the
intervention in reproducing a degree of variability of injec-
tion time that might be expected in usual daily life, as well as
the lack of any trend toward undesirable effects of this var-
iability. Limitations include the small numbers of partici-
pants enrolled and observation of participants for a period of
just 3 months (resulting in relatively low statistical power),
dependence on participant reports of the timing of dosing,
and some uncertainty as to whether the findings can be
generalized to longer-term periods of treatment or other
populations. Also, the variability resulting from the advice
given to the flexible-dosing group might be less than expe-
rienced by some individuals in daily life, and no comparison
with an alternative insulin product was included in the sub-
studies. Confirmation of the lack of untoward consequences
A B
C D
FIG. 3. Hypoglycemic events in each category (pooled EDITION 1 and EDITION 2 substudies; safety population).
(A) Percentage of participants experiencing one or more nocturnal (00:00–05:59 h) events in each category. (B) Percentage
of participants experiencing one or more events at any time (24 h). (C) Annualized nocturnal (00:00–05:59 h) rates (events
per participant-year). (D) Annualized rates (events per participant-year) at any time (24 h).
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of greater variability of injection timing will require larger
and longer studies in people with T2DM that can provide
greater statistical power. Studies of this issue in people with
type 1 diabetes would also be of interest.
In conclusion, the results suggest that allowing greater
variability of injection timing (24– up to 3 h) of Gla-300 in
the setting of a clinical study did not compromise efficacy and
safety profiles in people with T2DM. Therefore, Gla-300may
allow people with T2DM more freedom in timing their basal
insulin injections to deal with the situational variability ex-
perienced in daily life.
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